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Reseksjon av høygradige gliomer 
 
Høygradige gliomer er den vanligste formen for primær hjernesvulst. Glioblastomer 
(Verdens Helseorganisasjon grad IV) og anaplastiske astrocytomer (Verdens 
Helseorganisasjon grad III) utgjør mellom 70 og 85 % av høygradige gliomer. 
Høygradige gliomer er assosiert med både høy morbiditet og mortalitet. Nærmest alle 
pasienter med høygradige gliomer opplever tilbakefall og dør som følge av sykdommen. 
Til tross for kirurgi, strålebehandling og cellegift, er median overlevelse for pasienter 
med glioblastom fremdeles under 12 måneder. For pasienter med anaplastisk 
astrocytom er median overlevelse 2 til 3 år.  
 
Høygradige gliomer infiltrerer omkringliggende hjernevev, og hensikten med kirurgi er, 
foruten å histopatologisk verifisere diagnosen, å fjerne så mye av svulsten som mulig 
uten å påføre pasienten nye eller økte nevrologiske utfall. I vår avdeling benytter vi et 
navigasjonssystem under operasjonene som nyttiggjør tredimensjonale preoperative 
MR-bilder og tredimensjonal ultralydavbildning under operasjonen. Dette 
navigasjonssystemet gjør at kirurgen til en hver tid kan se posisjonen til sine 
instrumenter i forhold til hjernen og svulsten. Ved hjelp av funksjonell MR (eller mer 
presist blood-oxygenation-level-dependent functional magnetic resonance imaging) og 
diffusjon tensor traktografi (DTT) kan en henholdsvis kartlegge viktige områder i 
hjernens grå og hvite substans før operasjonen. Disse undersøkelsene utføres som regel 
når svulster ligger i nær relasjon til ekstra følsomme områder av hjernen (for eksempel 
språkområder og viktige områder for bevegelse). Informasjon fra disse undersøkelsene 
kan også importeres i navigasjonssystemet som benyttes under operasjonen.    
 
I de to første studiene i denne avhandlingen ønsket vi å undersøke hvordan funksjonell 
MR og DTT ble brukt i preoperative vurderinger. Vi evaluerte om funksjonell MR og 
DTT i kombinasjon med tredimensjonal ultralydavbildning under operasjonen la 
forholdene til rette for skånsom fjerning av høygradige gliomer beliggende i ekstra 
følsomme områder av hjernen. I den tredje studien undersøkte vi konsekvensene av 
kirurgiske komplikasjoner og nevrologiske utfall som følge av kirurgi på 
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glioblastompasienters funksjonsnivå og overlevelse. Videre gjorde vi volumetriske 
analyser for å beregne hvor mye svulstvev vi klarte å fjerne hos pasienter med primære 
glioblastomer behandlet i vår avdeling. I den fjerde studien undersøkte vi om det var 
noen sammenheng mellom overlevelse og fall i selvrapportert livskvalitet kort tid etter 
kirurgi hos pasienter med glioblastomer. Den femte studien var basert på data fra 
Kreftregisteret og undersøkte overlevelse og behandling blant eldre pasienter (≥66 år) 
med glioblastomer over en tyve års periode.  
 
Hovedfunnene i denne avhandlingen er: 
- Kombinasjonen av funksjonell MR, DTT og tredimensjonal ultralydavbildning 
kan være nyttig når en utfører kirurgisk reseksjon av høygradige gliomer 
beliggende i ekstra følsomme områder av hjernen. 
- Pasienter som opplevde komplikasjoner og nevrologiske utfall som følge av 
kirurgi hadde lavere sannsynlighet for å motta strålebehandling og kjemoterapi. 
- Tidlig fall i helserelatert livskvalitet etter kirurgi synes å være en sterk og 
uavhengig negativ prognostisk faktor for pasienter med glioblastom. 
- Økende alder er en sterk og uavhengig negativ prognostisk faktor for pasienter 
med glioblastom. Selv om det har vært en intensivering av behandling over tid, 
har gevinsten i den eldste aldersgruppen vært begrenset. Prognosen for de eldste 
er fremdeles svært dårlig til tross for multimodal behandling. 
 
Candidatus medicinae Sasha Gulati 
Nevrokirurgisk avdeling, St. Olavs Hospital 
Institutt for laboratoriemedisin, barne- og kvinnesykdommer, NTNU 
 
Hovedveileder: Professor dr.med Sverre H. Torp, NTNU 
Biveilder: Overlege Ph.D. Ole Solheim, NTNU 
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Surgical Resection of High-Grade Gliomas 
 
High-grade gliomas are the most common primary brain tumour. Glioblastomas (World 
Health Organization Grade IV) and anaplastic astrocytomas (World Health 
Organization Grade III) account for 70-85% of high-grade gliomas. High-grade gliomas 
are associated with high morbidity and mortality. Virtually all patients with high-grade 
glioma will experience recurrence and will eventually die from progressing disease. 
Despite surgery, radiotherapy, and chemotherapy, median survival in patients with 
glioblastoma still does not exceed 12 months. The median survival for patients with 
anaplastic astrocytoma (AA) has been reported to be between 2 and 3 years. According 
to current guidelines, surgery is warranted to establish a histopathologic diagnosis and 
to achieve safe, maximal, and feasible resection. However, these aggressive tumours 
cannot be cured and overly aggressive resection is not recommended due to the risk of 
new neurological deficits. High-grade glioma surgery is a delicate balance between 
achieving maximal tumour resection and inducing new deficits. 
 
In our department a neuronavigation system based on preoperative 3D magnetic 
resonance imaging (MRI) and intraoperative 3D ultrasound is utilised when resecting 
high-grade gliomas. Blood-oxygenation-level-dependent functional magnetic resonance 
imaging (BOLD fMRI) and diffusion tensor tractography (DTT) are specialized MRI 
techniques for imaging eloquent cortices and neural tracts in grey and white matter, 
respectively. The neuronavigation system allows the integration of BOLD fMRI and 
DTT data if the tumours are located in eloquent regions.  
 
In the two first studies of this thesis we sought to investigate the use of BOLD fMRI 
and DTT for preoperative assessments and determine whether using these data together 
with 3D intraoperative ultrasound enabled safe resection of high-grade gliomas situated 
in eloquent regions. In the third study we wanted to explore the impact of surgical 
morbidity on functional outcome and survival in GBM patients. Further, we sought to 
determine extent of tumour resection achieved in a consecutive sample of primary GBM 
from our own department. In the fourth study we wanted to determine if changes in 
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health related quality of life early after surgery could be a predictor for survival in 
patients with glioblastoma. The aims of the fifth study were to explore survival and the 
treatment provided to elderly patients (≥66 years) diagnosed with glioblastoma during a 
20-year time period in a population-based cohort using the Norwegian Cancer Registry.  
 
This thesis investigated the role of surgical resection in the treatment of high-grade 
gliomas and the following conclusions can be drawn: 
- The combination of BOLD fMRI, DTT, and 3D intraoperative ultrasound may 
facilitate resection of high-grade gliomas harboured in eloquent areas while 
preserving motor and language function. 
- Functional neuronavigation combined with intraoperative 3D ultrasound can, in 
most patients, enable resection of brain lesions with general anaesthesia without 
jeopardizing neurological function. 
- Patients with perioperative complications and surgically acquired deficits were 
less likely to receive adjuvant therapy. 
- Early deterioration in HRQL after surgery was independently and markedly 
associated with impaired survival in patients with glioblastoma. 
- Advancing age remains a very strong and independent negative prognostic 
factor in glioblastoma. Although there has been an increase in the 
aggressiveness of treatment provided to elderly with glioblastoma, the gain for 
the oldest age group seems at best very modest. The prognosis of the oldest age 
group remains very poor, despite multimodal treatment. 
 
 
Sasha Gulati M.D. 
Department of Neurosurgery, St. Olavs Hospital 
Department of Laboratory Medicine, Children’s and Women’s Health, NTNU 
 
Main supervisor: Professor Sverre H. Torp, NTNU 
Second supervisor: Ole Solheim M.D. Ph.D., NTNU 
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Introduction 
 
The Task at Hand 
 
High-grade gliomas are the most common primary brain tumours (139). Glioblastomas 
and anaplastic astrocytomas account for 70-85% of high-grade gliomas (134). The work 
presented in this thesis focuses on anaplastic astrocytomas and glioblastomas, 
collectively often referred to as high-grade astrocytomas. They are associated with 
tremendous morbidity and virtually all patients with will experience recurrence and die 
of progressive disease despite maximal therapeutic efforts. 
 
The median survival for patients with anaplastic astrocytoma (AA) has been reported to 
be between 2 and 3 years (69, 74). The majority of glioblastoma (GBM) patients, 
particularly the elderly, succumb to the disease within a year (69, 74). Even with 
maximal surgical resections using modern technical aids, and despite advances in 
radiotherapy and chemotherapy, the prognosis remains dismal. 
 
 
Classification of High-Grade Astrocytomas 
 
Gliomas arise from glial supportive tissue of the brain including astrocytes, 
oligodendrocytes, or ependymal cells (74). The astrocytic tumours represent the 
majority of the gliomas and show a wide range of differentiation and histopathological 
features. The World Health Organization (WHO) classifies astrocytomas on the basis of 
histologic features into four prognostic grades (74): grade I (pilocytic astrocytoma), 
grade II (diffuse astrocytoma), grade III (anaplastic astrocytoma), and grade IV 
(glioblastoma). Anaplastic astrocytoma and glioblastoma are commonly referred to as 
high-grade or malignant astrocytomas. Pilocytic astrocytomas are regarded as non-
infiltrating and are distinguished from the other forms by their particular pathological 
appearance and benign behaviour. They occur in children and young adults and are 
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usually located in the midline in structures such as the cerebellum, brain stem, 
hypothalamus, and optic nerves. WHO grade II, III, and IV astrocytomas, collectively 
also termed diffuse infiltrating astrocytomas, have a high recurrence rate due to the high 
propensity of infiltrating adjacent brain tissue. In addition, they have an intrinsic 
tendency to become more malignant over time, so a recurrent tumour is frequently of a 
higher malignancy grade. Actually, these tumours can be viewed as a continuum along 
an axis of increasing malignancy.  
 
The histological malignancy grading is based on the following features: cellularity, 
atypia, mitotic activity, necrosis, and microvascular proliferation. In Table 1 typical 
images and descriptions of diffuse astrocytomas grade II-IV are presented. Increasing 
malignancy is characterized by increasing cellularity, increasing number of mitoses, and 
cellular and nuclear atypia. Presence of microvascular proliferation and/or necrosis 
justifies the diagnosis of glioblastoma. Secondary glioblastomas develop from grade II 
or III astrocytomas, whereas primary or de novo glioblastomas occur without any 
previous history of a less malignant lesion. Amplification and overexpression of the 
epidermal growth factor receptor gene is the major genetic pathway in development of 
the secondary glioblastomas, whereas tumour protein 53 gene mutations are important 
in the development of primary glioblastomas (56). Typical routes of high-grade 
astrocytoma infiltration are the corpus callosum, internal capsule, fornix, anterior 
commissure, and optic radiation. On the other hand, glioblastomas tend not to grow into 
the leptomeninges and thus rarely metastasize via cerebrospinal fluid. Invasion of the 
dura, venous sinuses, and bone is also exceptional, and distant metastases are extremely 
rare (4, 8, 74).  
 
The histopathological diagnostics of diffuse astrocytomas can be challenging, and 
despite histopathological criteria given by the WHO, considerable interobserver 
variability exists. While there is usually a good concordance in diagnosis for 
glioblastomas between pathologists, disagreement in more than 30% of samples is 
common for anaplastic astrocytomas (120). 
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Table 1. WHO classification system for diffuse astrocytomas WHO grade II-IV (Photos 
provided by Prof. S. H. Torp) 
 
Grade II 
 
Moderate cell density 
Minor nuclear atypies 
Minor mitotic figures 
No necrotic areas 
 
Grade III 
 
High cell density 
Moderate nuclear atypies 
High rate of mitotic figures 
No necrotic areas 
 
Grade IV 
 
High cell density 
High rate of nuclear atypies 
High rate of mitotic figures 
High rate of necrotic areas 
Microvascular proliferations 
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Epidemiologic Features 
 
The incidence of WHO grade III and IV gliomas is approximately 5-7 cases per 100,000 
people per year (134, 136). Annually, approximately 25 adult patients are operated for 
primary GBM in our department (paper 3). Improved and more readily available 
neuroimaging may have slightly increased the incidence of malignant glioma, especially 
in the elderly (35). The incidence of GBM increases with advancing age, peaking 
between the ages of 65 to 84 (139). In the age group 65-74 the incidence is 13 per 
100,000 person-years and in the age group 75-84 it is 15 per 100,000 person-years (80). 
The mean age of primary GBM patients operated in our department between 2004 and 
2009 was 62 years (paper 3). For secondary GBM, the mean age is about 45 years 
(1).The median age of patients at the time of diagnosis is 45 years in the case of 
anaplastic gliomas (134). Malignant gliomas are rare in childhood, comprising between 
6-9% of all intracranial neoplastic disorders in the pediatric population (18, 32). 
 
In most patients with malignant astrocytomas no underlying cause can be identified. 
Inherited syndromes such as neurofibromatosis types 1 and 2, tuberous sclerosis, 
Cowden’s disease, Turcot’s syndrome, and Li-Fraumeni syndrome, predispose to 
developing astrocytomas (120, 134, 138). Age at diagnosis and Karnofsky performance 
score (KPS) are important and established prognostic factors in high grade glioma 
patients (36, 63). The only proven environmental risk factor for gliomas is exposure to 
ionizing radiation (35). Evidence for an association with occupational risk factors, use 
of cellular phones, certain foods, and exposure to electromagnetic fields is inconclusive 
(35, 41, 64, 134). Interestingly, an inverse association between atopy and the risk of 
glioma has been observed (71). 
 
 
Clinical features 
 
High-grade gliomas produce symptoms by a combination of focal neurologic deficits 
from compression and infiltration of the surrounding brain and raised intracranial 
pressure. Most patients with high-grade gliomas present with headaches, progressive 
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sensorimotor neurologic deficits, cognitive changes, or seizures (13). Corticosteroids 
are often administered before surgery to relieve tumour symptoms and improve 
neurological symptoms. 
 
 
Neuroimaging 
 
Imaging with CT or MRI will show a localized expansive process with associated 
oedema (120). On CT, GBM frequently present as irregularly shaped lesions with a 
peripheral ring-like area of contrast enhancement around a hypodense central area of 
necrosis. On enhanced MR images, the contrast-enhancing ring structure in GBM 
represents the cellular and highly vascularized peripheral area of the neoplasm and the 
dark centre corresponds to necrosis. Anaplastic astrocytomas often present as ill-defined 
masses with partial contrast enhancement, although both intense enhancement and non-
enhancement can be seen. Differential diagnoses for malignant gliomas include 
abscesses, metastases, primary central nervous system lymphomas, and other primary 
brain tumours (120). Proton MR spectroscopy is based on the measured intensity of 
several metabolites. This modality can be a useful supplement for differentiating gliosis 
or radiation necrosis from recurrent tumour in patients where repeated resection is 
considered (34). 
 
High-grade astrocytomas are larger than seen by any modern imaging technology, and 
the actual extension of a tumour is typically beyond what is indicated by CT and MR 
imaging. The greatest numbers of tumour cells can be found within the MRI-defined 
abnormality. However, stereotactic serial biopsies have shown that isolated tumour cells 
coexist with intact parenchyma in the peritumoural oedema surrounding the contrast-
enhancing area and as far as 7 cm from any MRI-defined abnormality (54). This means 
that tumour cells coexist with functional brain parenchyma, and that there usually is no 
defined border between infiltrated parenchyma and normal brain.  
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Treatment 
 
The first reported instance of surgery for cerebral glioma appears to have been 
performed by Godlee and Bennett in 1884 in London, England (9). Initially the patient 
did well, following what was considered to be a complete removal of a subcortical 
tumour, but succumbed to infectious complications on the 28th postoperative day. At 
this time there were no radiographic tests available. The preoperative localization of the 
tumour and the technical details of the procedure were graphically described by the 
authors since they felt that the localization of the tumour and its removal 'without any 
immediate injurious effects on the intelligence and general condition of the patient' were 
the main features of interest. In the following years, pioneers of neurosurgery such as 
Horsley, Cushing, Mackenzie, and Dandy presented a diversity of technical approaches 
and operative recommendations for gliomas (102). In the early twentieth century, 
meticulous hemostasis was introduced by Cushing with his development of the vascular 
clip and the electrocautery. This lead to a progressive decline in operative mortality 
(68). The next major advance was the advent of radiographic imaging, first with 
ventriculography introduced by Dandy and then with the discovery of cerebral 
angiography by Moniz and Lima (102). Over the past 40-50 years we have seen the 
introduction of technological appliances such as the operating microscope, image-
guided surgery, ultrasonic imaging, volumetric stereotaxy, intraoperative CT and MR 
imaging, and fluorescence guided surgery (53). These discoveries have further 
contributed to reduce perioperative morbidity and mortality rates (86).  
 
Current treatments for patients with malignant glioma include surgery, radiation 
therapy, and chemotherapy. Surgery has become the cornerstone in the initial treatment 
of high-grade gliomas, and is the most efficient method for the reduction of tumour 
burden available. There is now level 2b data (Oxford Centre for Evidence-based 
Medicine) showing that gross total resection (resection of contrast enhancing tissue on 
T1 MRI) prolongs survival (116). According to current guidelines surgery is warranted 
to establish a histopathologic diagnosis and to achieve safe, maximal, and feasible 
resection (20, 27, 29, 36, 78, 106). However, these aggressive tumours are only rarely 
cured (24) and overly aggressive resection is not recommended due to the risk of new 
 19 
neurological deficits. High-grade glioma surgery is a delicate balance between 
achieving maximal tumour resection and inducing new deficits.  
 
Radiotherapy has been shown to add several months to survival (61, 133), and has 
become part of the standard of care. Postoperative fractionated external-beam 
radiotherapy is routine. It is usually administered as 60 Gy in 30 fractions over a period 
of about six weeks. Evidence supporting the use of radiotherapy in the elderly was 
provided by a randomized controlled trial (RCT) where patients who underwent surgery 
were allocated to radiotherapy or supportive care only (51). This study from 2007 
showed that patients above 70 years with Karnofsky performance status score ≥70 
undergoing radiotherapy may experience a modest survival benefit compared to 
supportive care (median 29.1 vs. 16.9 weeks). Less aggressive radiotherapy protocols 
have been advocated in older patients. An RCT in patients 60 years or older compared 
standard normofractioned radiotherapy (60 Gy in 30 fractions over 6 weeks) to a 
hypofractioned regimen (40 Gy in 15 fractions over 3 weeks) and found similar survival 
in the two groups (97). In a younger, fairly unselected population (<70 years), lower 
radiotherapy doses (45 Gy over 4 weeks vs. 60 Gy over 6 weeks) were associated with 
both inferior progression-free and overall survival (14). 
 
In 2005 Stupp et al published an RCT comparing radiotherapy alone with radiotherapy 
plus the alkylating agent temozolomide (119). The addition of temozolomide to 
radiotherapy showed a survival benefit with little additional toxicity. Median survival 
was 14.6 months with radiotherapy and temozolomide, and 12.1 months with 
radiotherapy alone. This in turn resulted in a shift from the intravenously administered 
PCV treatment to the orally administered temozolomide. 
 
Recurrent tumour is more difficult to treat. These patients may be considered for 
surgery again if they have a good performance status (43). Re-do radiotherapy may be 
an option in selected patients, although increased toxicity may be a problem. Many 
neuro-oncologists recommend re-do adjuvant temozolomide in patients who did not 
progress while on their first course of chemotherapy (1).  
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Surgical Procedures  
 
All craniotomies are performed in general anaesthesia without intraoperative 
electrocortical mapping. The patient’s head rests in a Mayfield frame system (OMI, 
Inc., Cincinnati, OH, USA) attached to a reference frame for neuronavigation. In our 
department the Sonowand® neuronavigation system, based on preoperative 3D MRI 
data and intraoperative 3D ultrasound is utilised when resecting malignant gliomas (38, 
126). The 3D ultrasound volume is reconstructed from 100-200 2D images, created by 
making a recording over the area of interest with a tracked ultrasound probe. The 
preoperative MRI data are imported into the navigation system and used for surgical 
planning and resection guidance. Intraoperative 3D ultrasound can be used alone for 
navigation, but we usually register preoperative 3D MR volumes to the patient’s head 
before commencing surgery. The neuronavigation system also allows the integration of 
high-quality blood oxygenation-level-dependent functional magnetic resonance imaging 
(BOLD fMRI) and diffusion tensor tractography (DTT) data if the tumours are located 
in eloquent regions (95).  
 
There is always some inaccuracy when the preoperative images are registered to the 
patient (registration inaccuracy). In addition, there may be inaccuracy in the navigation 
system itself (technical inaccuracy). Moreover, craniotomies lead to a displacement or 
shift of intracranial structures. The main reasons for brain shift are removal of 
cerebrospinal fluid and tumour tissue. The brain shift is usually most pronounced at the 
cortical surface, whereas it is smaller in deeper structures of the brain. For 3D 
ultrasound, the registration inaccuracy is eliminated as both ultrasound acquisition and 
navigation based on 3D ultrasound volumes are performed in the same system. Updated 
intraoperative ultrasound volumes can be acquired several times during surgery in order 
to minimise and detect possible errors of brain shift. 
 
The first ultrasound volume is usually acquired after the craniotomy has been performed 
and before opening of the dura. The multimodal 3D data sets from intraoperative 
ultrasound and preoperative MRI, BOLD fMRI, and DTT are used for resection control 
and guidance. The Cavitron ultrasonic aspirator (CUSA) is applied to fragment and 
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aspirate the tumours. If desired, an attached tracking frame can be used for tracking of 
the CUSA in the image volumes. The position of the tip and the trajectory of the CUSA 
can be monitored in the MRI and updated ultrasound volumes for close to real-time 
resection guidance. The navigation system also allows visualization of vessels based on 
recordings of power Doppler signals from the blood stream, which also may be of use in 
tumour operations (100).  
 
Biopsies are useful for histopathological classification, although there is a risk of 
sampling error. Gliomas are often heterogeneous, and it is a concern that small tissue 
samples through a biopsy may not be representative of the tumour as a whole. A 
prospective study of patients undergoing biopsy first and then resection a few weeks 
later, found that biopsy correctly guided therapy in 91% of the patients (137). Biopsies 
are also performed when there is considerable doubt concerning the etiology of a brain 
lesion (e.g. glioma vs. lymphoma). If necessary, patients can undergo subsequent 
tumour resection after a biopsy procedure. Biopsy is considered a low risk procedure, 
with a morbidity rate from retrospective series of around 3.5% and a mortality rate of 
less than 1% (40). Biopsy may be preferred over resection in patients with poor 
functional performance status, of older age, or when the tumour is in an anatomically 
prohibitive location for resection (e.g. in deep regions), although the biopsy rates can 
vary much from centre to centre.  
 
 
Functional Imaging and Mapping of Eloquent Brain Areas 
 
Eloquence can be defined as fluent, forcible, elegant or persuasive speaking. However 
in neurosurgery, the term has been adopted to describe regions of the brain that control 
speech, motor functions, and senses. Surgical resection of lesions surrounding the 
eloquent brain areas is often a challenge. In cases of high-grade astrocytomas located 
within or adjacent to the central sulcus, basal ganglia, and subcortical motor pathways, 
it is often hard to intraoperatively perceive the relationship between lesions and 
functional structures of the sensorimotor cortex and pyramidal tracts. Even in the 
normal brain there is variability between function and anatomy. In case of undistorted 
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anatomy, eloquent areas may be recognized using specific sulcal landmarks. As an 
example, hand-function can be located at the omega-shaped structure of the “hand 
region” in the precentral gyrus (143). Mass effect associated with high-grade gliomas 
can distort these common relations, making anatomy-based localization of functional 
areas more challenging. Functional regions may also be relocated to other brain areas, 
thereby changing the normal relationships between function and anatomy (130).  
 
Intraoperative electrical motor cortex mapping and recording phase reversal of 
somatosensory evoked potentials have traditionally been considered as gold standard 
when performing surgery close to eloquent cortex. The classic procedure for language 
localization is intraoperative electrocortical mapping in awake and cooperative patients 
(90, 104). Motor mapping can be performed while the patient receives a general 
anaesthetic. These techniques do not assist in preoperative planning, and intraoperative 
mapping often requires a craniotomy larger than necessary with respect to the tumour to 
be resected (104, 130). In recent years the technique of preoperative mapping of 
functionally important brain areas has made advances. Positron emission tomography, 
functional magnetic resonance imaging (fMRI), and magnetoencephalography have 
been used as tools for the localization of sensorimotor cortex.  
 
Blood oxygenation-level-dependent (BOLD) fMRI may be applied for mapping of 
eloquent cortices using colour-coded statistical parametric maps overlaid on the 
anatomical images of the brain. Diffusion tensor imaging (DTI) can be used for 
mapping of neural tracts in the white matter, which through an analysis called diffusion 
tensor tractography (DTT) can visualize the neural tracts as 3D fibre bundles. The 
information obtained through fMRI and DTT is matched and fused with high-resolution 
MR images. The integration of fMRI and DTI activation maps into neuronavigation is 
often referred to as “functional neuronavigation”. 
 
The physical basis for the BOLD signal is provided by the properties of 
deoxyhemoglobin, which is paramagnetic and has the ability to influence the MRI 
signal (87). Changes in the level of deoxyhemoglobin compared to oxyhemoglobin will 
give rise to a variation in the measured MRI signal, known as the BOLD signal (88). 
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The physiological basis for the BOLD signal lies in changes of blood flow, volume, and 
level of oxygenation following neuronal activity, also referred to as the neurovascular 
coupling (16).  
 
A BOLD fMRI investigation consists of several steps, starting with a patient inside an 
MRI-scanner performing particular tasks at given times while magnetic resonance 
images are acquired. These images then need to be pre-processed before statistical 
analyses are performed, in order to produce colour-coded statistical parametric 
activation maps. The activation maps are then co-registered to anatomical images. The 
process from image acquisition to interpreted functional maps consists of several steps 
each vulnerable to different sources of error (11, 17, 89, 130). Many stimulation 
paradigms have been used for preoperative mapping, the most commonly mapped 
functions being sensorimotor functions, language generation (often referred to as 
Broca’s area), language perception (often referred to as Wernicke’s area), and vision. It 
is important that the patient is able to lie still when solving the task, as movement of the 
head during scanning produces signal distortions. Motion is the most important reason 
for unsuccessful BOLD fMRI investigations (44, 59). The ability to correctly carry out 
the tasks may vary with patients’ cognitive function and intracranial pathology. There 
are no standardized tasks, scanning procedures, administration of tasks, pre-processing 
or interpretation of activations for clinical applications of BOLD fMRI, which makes 
comparisons between publications difficult (121, 130).  
 
The validity of fMRI in detecting sensorimotor activation has been evaluated in a 
number of studies (7, 98, 141, 144). One of the largest studies compared the results of 
fMRI motor areas co-registered into neuronavigation with electric cortical stimulation 
in 32 patients who underwent surgery for a brain tumour or for chronic pain (98). There 
was a good correlation between the two methods in 87% of the patients, and the authors 
found the fMRI data helpful in surgical planning and guiding intraoperative brain 
mapping. A similar study with 18 patients undergoing surgery for a brain tumour, found 
that the fMRI sensitivity for localizing the primary hand motor cortex detected by 
electrostimulation was 71% (7). The authors urge caution when using the results of 
fMRI in intraoperative navigation, and recommend that it is combined with electric 
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cortical stimulation. There are few studies focusing on validation of functional MR 
imaging in detecting language cortices, and results are conflicting (12, 98, 99). When it 
comes to resecting tumours in close proximity to language areas, the role of BOLD 
fMRI in detecting language cortices has not yet reached the status of full clinical 
acceptance. Although some believe that BOLD fMRI still cannot replace intraoperative 
electrocortical stimulation mapping, it has also been suggested that it can be used to 
speed up intraoperative electrocortical mapping procedures and to guide the extent of 
the craniotomy. 
 
Some studies have shown that the BOLD response in the vicinity of tumours does not 
reflect the neuronal signal as precisely as in healthy brain tissue. Schreiber et al report 
that fMRI activation is reduced near glial tumours, whereas it is not affected by non-
glial tumours (107). It is suggested that this might be due to the infiltrative growth of 
gliomas. In paretic brain tumour patients, studies have also shown a smaller BOLD 
response in the primary motor area (60, 94). The reasons for this may be altered cortical 
function or altered hemodynamic response, or both. 
 
Diffusion tensor imaging (DTI) is developed from diffusion weighted MRI. DTI 
enables the measurement of the anisotropic diffusion of water in neural fibre bundles. It 
can give delineations of white matter tracts that do not show up on other forms of MRI 
scanning. The fractional anisotropy (FA) map is the principal form of DTI post-
processing images. Another way of presenting the DTI images is through fibre tracking 
or diffusion tensor tractography (DTT). Fibre tracking algorithms can be used to track a 
fibre along its whole length (for example within the pyramidal tract) (11). Suggested 
tracts need to be manually and individually processed with a region-of-interest tool to 
virtually dissect plausible tracts of interest by choosing anatomical localization tracts 
are known to run within. For the pyramidal tract, potential region-of-interests are the 
cerebral peduncles, posterior limb of the internal capsule, and the superior part of the 
precentral gyrus. In this way the fibres can be tracked from the motor cortex to the 
spinal cord. Two studies have provided intraoperative electrophysiological verification 
of DTI-based functional neuronavigation (10, 31). Wu et al conducted an RCT to assess 
the contribution of functional neuronavigation with DTI in glioma surgery (140). They 
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used DTI to delineate the pyramidal tract in fractional anisotropy maps and registered 
these data with the navigation datasets for intraoperative guidance. Compared with the 
control group, in which the patients underwent operation with navigation guidance 
without visualization of the pyramidal tract, they achieved a significant reduction of 
postoperative neurological deficits, a higher number of gross total resections, improved 
Karnofsky Performance Scale score, and improved survival in high-grade gliomas.  
 
Unlike BOLD fMRI, a DTI investigation does not require the patient to perform a task. 
The patient only needs to lie still while the images are acquired. The main reasons for 
reduced quality of DTI are related to pathological processes such as tumour oedema and 
compression of the white matter tracts. White matter regions where there are several 
fibre bundles with different orientations or where they “kiss”, cross, merge or diverge, 
are particularly troublesome for the tracking algorithms (28, 79).  
 
It is important to remember that knowledge of the exact position of functional cortices 
and white matter tracts can not entirely prevent neurological deficits. Intraoperative or 
postoperative events such as damage to passing or adjacent vessels or postoperative 
hematomas may result in circulatory changes in functional areas, leading to neurological 
deficits.  
 
 
Adverse Events 
 
Risk of adverse events related to treatment is considerably high in neurosurgery 
compared with many other medical specialties (49). Focus on adverse events has the 
potential to improve quality of care. At present there is no accepted, uniform way of 
reporting adverse events in neurosurgical series. Thus, comparisons between various 
publications are often not feasible. The list of adverse events that can occur during or 
after resection of malignant astrocytomas is exhaustive. Adequate planning may 
presumably decrease the risk of complications. This includes detailed study of the 
preoperative magnetic resonance imaging, neuronavigation, and surgical and 
interdisciplinary team discussion. Specific thought should be placed on the indication 
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for surgery and the surgical aim (i.e. gross total resection, subtotal resection, or biopsy).  
The patient’s general physical status should be optimized including the management of 
increased intracranial pressure. Complete work-up and preparation by the 
anaesthesiologist and eventually other specialists is often performed in hope of limiting 
systemic complications. 
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Aims and Methodological Considerations 
 
The overall aim of this thesis was to study the role of surgical resection in the treatment 
of high-grade astrocytomas. 
 
Paper 1 
Surgical resection of high-grade gliomas in eloquent regions guided by 
blood oxygenation level dependent functional magnetic resonance imaging, 
diffusion tensor tractography, and intraoperative navigated 3D ultrasound 
We sought to determine clinical outcome, extent of tumour resection, and the 
practical usefulness of BOLD fMRI and DTT in patients with high-grade 
gliomas in eloquent regions. 
 
Paper 2 
Functional magnetic resonance imaging and diffusion tensor tractography 
incorporated into an intraoperative 3-dimensional ultrasound-based 
neuronavigation system: impact on therapeutic strategies, extent of 
resection, and clinical outcome 
We sought to assess the use of fMRI and DTT for preoperative assessments and 
determine whether using these data together with 3D ultrasound during surgery 
enabled safe lesion resection in eloquent locations.  
 
Paper 3 
The risk of getting worse: Surgically acquired deficits, perioperative 
complications and functional outcomes after primary resection of 
glioblastoma 
We sought to explore the impact of surgical morbidity on functional outcome 
and survival in GBM patients.  
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Paper 4 
Postoperative deterioration in health related quality of life as predictor for 
survival in patients with glioblastoma: a prospective study 
The aim was to determine if changes in health related quality of life could be a 
predictor for survival in patients with glioblastoma. 
 
Paper 5 
Survival and treatment patterns in elderly patients with glioblastoma – A 
population based study 
The aims of this study were to explore survival and the treatment provided to 
elderly patients (≥66 years) diagnosed with glioblastoma in a population-based 
cohort using data from the Norwegian Cancer Registry. 
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Patient Population 
 
All patients included in papers 1, 2, 3, and 4 were treated at the Department of 
Neurosurgery, St. Olavs University Hospital. The retrospective inclusion of patients in 
studies 1, 2 and 3 was done through systematic searches in hospital records. Prospective 
inclusion of patient data based on informed consent was used in study 4. Patients were 
otherwise selected according to the inclusion and exclusion criteria of each study. 
 
Study data in paper 5 were provided by the Norwegian Cancer Registry. Reports to the 
Norwegian Cancer Registry have been compulsory by law since 1952. All neoplasms 
and certain precancerous lesionsare to be registered. Cancer information comes from 
several independent sources, thus securing a high grade of completeness and quality of 
data. Since 1993 the Norwegian Cancer Registry has also included primary intracranial 
neoplasms that are solely based on a clinical diagnosis (i.e. neuroimaging) without 
histological verification. The completeness of patient registration has improved over the 
years, especially for non-operated cases. There is presumably no other systematic bias 
in missing data. A study from 2001-2005 demonstrated a 93.8% completeness of data in 
all central nervous system tumours, including cases without histological verification 
(67)  
 
 
Ethical Approval 
 
All studies were approved by the Regional Committee for Medical Research Ethics in 
Health Region Mid-Norway. Storage of data was approved by the Norwegian Social 
Science Data Services. Study protocols adhered to guidelines of the Helsinki 
Declaration. Studies 1, 2, and 3 were also approved by the Norwegian Ministry of 
Health, which allowed for review of patient data without informed consent.  Study 4 
was prospective and based on informed consent. 
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Surgery 
 
Patients presented in studies 1, 2, 3, and 4 were operated at the Department of 
Neurosurgery, St. Olavs Hospital. The commercially available ultrasound-based 
neuronavigation system Sonowand was used in the operations. Patients underwent 
anatomical and functional MRI investigations within 72 hours prior to surgery. 
Preoperative functional MRI used in most eloquent lesions and aimed at identifying 
motor and/or language cortices and diffusion tensor tractography sought to identify the 
corticospinal tract, the optic radiation or the arcuate fasciculus. The preoperative data 
were imported into the Sonowand system and used for surgical planning and guidance. 
Intraoperative 2D and 3D ultrasound volumes were acquired when desired during 
surgery and the multimodal data were used for guidance and resection control. Brain 
shift and changes in structural anatomy during surgery were detected with intraoperative 
ultrasound. 
 
 
Assessment of Tumour Resection and Eloquence 
 
Patients in our department routinely undergo 1.5 T or 3.0 T contrast-enhanced MRI 
scans a few days before and within 72 hours of surgery. The assessment of tumour 
resection grades in all papers were based on these pre- and postoperative MRI 
investigations. To determine resection grades in paper 1 and paper 2, tumour borders 
were segmented manually in each slice of pre- and postoperative T1-weighted or T1-
weighted contrast enhanced MRI images. Tumour volumes were calculated based on the 
voxel resolution and the total number of voxels segmented. In paper 3 and paper 4 
tumour volumes were determined using an ellipsoid volume formula (4/3·лr1r2r3) based 
on the maximum tumour diameters in the perpendicular dimensions (113, 115). In paper 
2, lesion to eloquent area distance (LEAD) was used as a measurement of tumour 
location relative to functional areas. A more feasible grading system for 
intraparenchymal brain tumours according to functional location has been presented by 
Sawaya (106) and this was used in paper 4.  
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Summary of Papers 
 
Paper 1 
 
Surgical resection of high-grade gliomas in eloquent regions guided by blood 
oxygenation level dependent functional magnetic resonance imaging, diffusion 
tensor tractography, and intraoperative navigated 3D ultrasound 
Gulati S, Berntsen EM, Solheim O, Kvistad KA, Håberg A, Selbekk T, Torp SH, 
Unsgård G 
Minimally Invasive Neurosurgery 2009  
 
The aims of this study of patients with high-grade gliomas in eloquent brain areas were 
1) to assess the postoperative functional outcome, 2) to determine the extent of tumour 
resection in these difficult locations, 3) to evaluate the practical usefulness of navigated 
blood oxygenation level-dependent functional magnetic resonance imaging and 
diffusion tensor tractography. 
In this study 25 consecutive patients were included. The patients' gross functional 
neurological status was determined using the 7-step mRS. The extent of tumour 
resection was determined using pre- and postoperative T(1)-weighted or T(1)-weighted, 
contrast-enhanced MRI images. 
The average preoperative modified Rankin scale was 1.56+/-0.77, whereas the average 
postoperative modified Rankin scale was 1.08+/-1.29. There was a significant 
improvement in mean modified Rankin scale score after surgery. The mean percentage 
of residual tumour was calculated to 16+/-22% of the original tumour volume (median 
8%). Blood oxygenation level-dependent functional magnetic resonance imaging and 
diffusion tensor tractography were performed in 23 and 18 patients, respectively. Blood 
oxygenation level-dependent functional magnetic resonance imaging and diffusion 
tensor tractography facilitated identification of probable functional regions in 91% and 
94% of the respective investigations. 
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We believe that the combination of blood oxygenation level-dependent functional 
magnetic resonance imaging, diffusion tensor tractography, and 3D ultrasound 
facilitated maximal tumour resection with minimal deficits. The method permits an 
image-based functional monitoring of the brain during surgery that may aid the 
preservation of motor and language function. 
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Paper 2 
 
Functional magnetic resonance imaging and diffusion tensor tractography 
incorporated into an intraoperative 3-dimensional ultrasound-based 
neuronavigation system: impact on therapeutic strategies, extent of resection, and 
clinical outcome 
Berntsen EM, Gulati S, Solheim O, Kvistad KA, Torp SH, Selbekk T, Unsgård G, 
Håberg AK 
Neurosurgery 2010  
 
In this study, functional magnetic resonance imaging (fMRI) and diffusion tensor 
tractography (DTT) were used to map eloquent areas. We assessed the use of fMRI and 
DTT for preoperative assessments and determined whether using these data together 
with 3D ultrasound during surgery enabled safer lesion resection. 
We reviewed 51 consecutive patients with intracranial lesions in whom fMRI with or 
without DTT was used to map eloquent areas. To assess a possible impact of 
fMRI/DTT, we reviewed and analyzed the quality of the fMRI/DTT data, any change in 
therapeutic strategies, lesion to eloquent area distance (LEAD), extent of resection, and 
clinical outcome. 
As a result of the fMRI/DTT mapping, the therapeutic strategies were changed in 4 
patients. The median tumour residue for glioma patients was 11% (n = 33). For gliomas, 
there was a significant correlation between decreasing LEAD and increasing tumour 
residue. Of the glioma patients, 42% underwent gross total resection (≥95%) and 12% 
suffered neurological worsening after surgery. Of glioma patients with an LEAD of ≤5 
mm, 24% underwent gross total resection and 10% experienced neurological 
deterioration. 
This study demonstrates that preoperative fMRI and DTT had direct consequences for 
therapeutic strategies and indicates their impact on intraoperative strategies to spare 
eloquent cortex and tracts. Functional neuronavigation combined with intraoperative 3D 
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ultrasound may, in most patients, enable resection of brain lesions with general 
anaesthesia without jeopardizing neurological function. 
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Paper 3 
 
The risk of getting worse: Surgically acquired deficits, perioperative complications 
and functional outcomes after primary resection of glioblastoma 
Gulati S, Jakola AS, Nerland US, Weber C, Solheim O  
World Neurosurgery 2011 
 
Gross total resection (GTR) prolongs survival, but is unfortunately not achievable in the 
majority of patients with GBM. Cytoreductive debulkings may relieve symptoms of 
mass effect, but it is unknown how long such effects sustain and to what degree the 
potential benefits exceed risks. We explore the impact of surgical morbidity on 
functional outcome and survival in unselected GBM patients. 
 
We retrospectively reviewed 144 consecutive adult patients operated for primary GBM 
at a single institution between 2004 and 2009. 141 (98%) operations were resections 
whilst 3 (2%) were biopsies. A decrease in Karnofsky performance status (KPS) scores 
was observed in 39% of patients after 6 weeks. On average, there was a significant 
decrease between pre- and postoperative KPS scores (p<0.001). 22 (15.3%) patients had 
new neurological deficits. Among patients who underwent surgical resection, those with 
new neurological deficits were less likely to receive radiotherapy (p<0.001), 
normofractioned radiotherapy (p=0.010), and chemotherapy (p=0.003). 28 (19.4%) 
patients had perioperative complications. Among patients who underwent surgical 
resection, those with perioperative complications were less likely to receive 
normofractioned radiotherapy (p=0.010) and chemotherapy (p=0.009). Age (p=0.019), 
new deficits (p<0.001), and surgical complications (p=0.006) were significant 
predictors for worsened functional outcome after 6 weeks. GTR (p=0.035), 
perioperative complications (p=0.008), radiotherapy (p<0.001), and chemotherapy 
(p=0.045) were independent factors associated with 12 month postoperative survival. 
 
Patients with perioperative complications and surgically acquired deficits were less 
likely to receive adjuvant therapy. While cytoreductive debulking may not improve 
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survival in GBM, it may decrease the likelihood of patients receiving adjuvant therapy 
that does. 
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Paper 4 
 
Postoperative deterioration in health related quality of life as predictor for 
survival in patients with glioblastoma: a prospective study 
Jakola AS, Gulati S, Weber C, Unsgård G, Solheim O 
PLoS ONE 2011 
 
The aim of this study was to assess if changes in health related quality of life (HRQL) 
was a predictor for survival in patients with glioblastoma. Studies indicate that acquired 
deficits negatively affect patients’ self-reported HRQL and survival, but the impact of 
HRQL deterioration after surgery on survival has not been explored.  
 
Sixty-one patients with complete HRQL data were included. HRQL was assessed using 
EuroQol 5D (EQ-5D), a generic instrument. HRQL data were collected 1-3 days 
preoperatively and after 6 weeks. The mean change in EQ-5D index was -0.05 (95 % CI 
-0.15 – 0.05) 6 weeks after surgery (p=0.285). There were 30 (49.2 %) patients 
reporting deterioration 6 weeks after surgery, forming the basis for the analysis 
concerning association between change in HRQL data and survival. In a Cox 
multivariate survival analysis we evaluated deterioration in HRQL after surgery 
together with established risk factors (age, preoperative condition, radiotherapy, 
temozolomide and extent of resection). 
 
We found significant independent associations between survival and use of 
temozolomide (HR 0.30, p=0.019), radiotherapy (HR 0.26, p=0.030), and deterioration 
in HRQL after surgery (HR 2.02, p=0.045). Inclusion of surgically acquired deficits in 
the model did not alter the conclusion and actually strengthened the association between 
deterioration in HRQL after surgery with overall survival (HR 2.4, p=0.022). 
 
Early deterioration in HRQL after surgery was independently and markedly associated 
with impaired survival in patients with GBM. Deterioration in patient reported HRQL 
after surgery is a meaningful outcome in surgical neuro-oncology, as HRQL reflects 
both the burden of symptoms and treatment hazards. 
 38
Paper 5 
 
Survival and treatment patterns in elderly patients with glioblastoma – A 
population based study  
Gulati S, Jakola AS, Johannesen TB, Solheim O 
World Neurosurgery 2012 
 
The aims of this study were to explore survival and the treatment provided to elderly 
patients (≥66 years) diagnosed with GBM between September 1988 and September 
2008 in a population-based cohort using the Norwegian Cancer Registry. From the 
Norwegian Cancer Registry, we included 2882 patients who were diagnosed with 
glioblastoma between September 1988 and September 2008.  
 
The proportion of patients ≥66 years was 42.5 % (n =1224), and 15.9% of patients (n = 
459) were ≥75 years at diagnosis. We found that treatment patterns varied significantly 
between age groups. Elderly patients were more likely to receive supportive care only 
and resection only and less likely to receive multimodal treatment with resection 
combined with radiation and/or chemotherapy. In addition, elderly patients were more 
likely to receive a diagnosis of GBM without histopathological verification. Among 
patients receiving multimodal treatment with resection, radiation, and chemotherapy, 
there was statistically significant shorter survival in the age groups 66-74 years and ≥75 
years. Belonging to the age group ≥75 years was identified as the strongest predictor of 
decreased survival. Increasing age, no tumour resection, no radiation, and no 
chemotherapy were identified as independent predictors of reduced survival. There was 
a statistically significant survival advantage for patients diagnosed in the last five years 
of the study. 
 
There is still a need for clinical studies to clarify the role of treatment modalities in all 
patients with GBM. The evaluation of surgical resection, radiotherapy and 
chemotherapy must involve patients with demographic characteristics that are 
representative of the majority of patients with glioblastoma, and elderly patients can 
therefore no longer be excluded. Providing guidelines on GBM resection to the elderly 
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on the basis of trial information obtained mainly from younger patients is not 
recommended as age remains a very strong and independent prognostic factor. 
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Discussion 
 
The vast amount of medical technical publications indicates that there are very sincere 
efforts going on to improve safety and quality in high-grade glioma surgery. However, 
defining, measuring, and reporting outcomes in this field of research are difficult 
challenges. In the research presented in this thesis, we have used several different 
outcome parameters including overall survival, resection grades, functional outcomes, 
adverse events, and patient reported health related quality of life. We have experienced 
that defining quality in high-grade glioma surgery remains an elusive task.   
 
 
Extent of resection and its impact on survival 
 
In papers 1 and 2, one of the aims was to determine the extent of tumour resection in 
patients with malignant astrocytomas located in eloquent regions. Pre- and 
postoperative tumour volumes were also provided for the patients in paper 3. A central 
question in neuro-oncology is whether more extensive resections of malignant gliomas 
are beneficial to patients. In the last decade numerous studies investigating the impact 
of resection on survival have been published. There are both studies which advocate 
more extensive resections (22, 23, 63, 65, 84, 105, 114, 117, 127) and those in which 
the statistical analyses did not favour any resection group (52, 70, 92, 93, 125). Most are 
retrospective series where direct comparisons are compounded by differences in patient 
characteristics, surgical technique, and outcome assessment and reporting.  
 
As for patient characteristics, factors such as age, time of enrolment, preoperative 
functional status, eligibility for GTR, tumour location, and tumour size may be 
associated with outcome. Biopsy or limited resections may more often be preferred in 
patients with poor performance status, of older age, or when the tumour is in an 
anatomically prohibitive location for gross total resection. Survival comparisons in 
retrospective studies are often made between patients who have merely been biopsied 
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and those who have undergone resection (103). This selection bias makes it difficult to 
assess the impact of resection on postoperative survival.   
 
The manner in which the extent of resection is calculated is also of importance. Many 
studies rely on the surgeons’ reports or two-dimensional analysis based on postoperative 
MRI scans. Surgeons’ estimates of resection grades are often inaccurate and they have a 
tendency to estimate a more radical resection than calculated from postoperative MRI 
imaging (113). Most studies divide resections qualitatively into gross total, subtotal, and 
partial or biopsy categories. However, the definition of gross total resection may vary 
between studies.  Volumetric MRI analysis is now regarded as the accepted standard 
(103), but is only provided in a few studies (52, 63, 92, 105, 117). 
 
Some studies recruit patients from previously conducted prospective trials (103). As a 
histological verification of the diagnosis is mandatory, nearly all these trials enrol 
patients after recovery from surgery. However, there are often predefined lower bounds 
of functional performance status at the time of inclusion. This means that patients who 
suffered significant morbidity or died perioperatively were excluded due to the study 
design. This can result in a selective loss of patients injured by the treatment which is 
assessed.  
 
Even though maximal safe surgical resection is advocated (20, 134), the role of 
incomplete tumour resection in prolonging survival is controversial (58, 77, 131). If 
resection is performed it seems like it needs to be extensive to affect survival. In a 
frequently cited retrospective study, 416 consecutive patients with GBM who 
underwent tumour resection were analysed. A statistically significant survival 
advantage was associated with resection of 98% or more of the tumour volume (63). 
Some limitations have been pointed out in the methodology of this paper (82, 105). 
Most importantly the study included both newly diagnosed and recurrent GBM, and the 
timing of postoperative imaging acquisition was inconsistent. The statistical methods 
used in an article can greatly influence results. In a recently published retrospective 
study with 500 patients by Sanai et al (105), it is claimed that subtotal resections as low 
as 78% correspond to a survival benefit. However, the 78% cut-off seems to be found in 
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univariate analyses only, apparently through an explorative approach with serial 
dichotomizations in Kaplan Meier curves. In search of the resection threshold, serial 
Kaplan-Meier survival curves were generated at 2% extent of resection intervals. This 
method did not account for confounding or effect modification by other covariates. 
Achieved resection grades and overall survival are affected by several patient and 
tumour characteristics, making this an important flaw of the study (111). Moreover, 
multiple pair-wise comparisons are known to produce cumulative type I errors 
increasing the risk of false positive findings. 
 
A post-hoc analysis of 243 patients involved in a trial of 5-ALA showed that extent of 
resection has a positive correlation with survival (117), but only so-called complete 
resection (i.e. GTR) had an impact on survival. All patients in the ALA-study were 
eligible for complete resection. Patients in this study were randomised to resection of a 
primary high-grade glioma by either white light or fluorescence guided resection (with 
orally administered 5-ALA). However, external validity is low in this study since 
patients were very highly selected, not reflecting those in routine clinical practice. 
 
For the majority of patients with GBM, GTR cannot be achieved. GTR is usually 
achieved in less than 20% in more or less unselected patient series with postoperative 
imaging (2, 6, 57, 109, 129). In a pooled analysis of 893 patients from several phase II 
GBM studies, resection of >90% of the tumour volume (NTR or better) was only seen 
in 17% (25). In paper 3 we achieved GTR in one third of the patients, which is good 
compared to other unselected series in the literature. 
 
In paper 3, only GTR (defined as ≥98% tumour removal) was associated with prolonged 
survival in a multivariate analysis (p=0.035). The statistical method used in this paper 
can be criticized as we used a minimum probability value method (3). Unfortunately, 
this strategy is associated with an increase in the false-positive rate. This strategy 
attempts to define a statistical cut-off by categorizing the data set into two groups on the 
basis of a single variable, in our case extent of resection. Further, inclusion of a cut-off 
determined in such a manner as a binary variable in the Cox multiple regression 
analysis can lead to an inflated effect at the expense of other variables. 
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There are clear limitations in the data examining the effect of subtotal resection on 
postoperative survival. Due to the lack of evidence it is difficult to establish convincing 
guidelines for extent of resection of malignant gliomas. Each institution has to 
determine if the quality of evidence is sufficient to influence their practice standards. 
There is still a need for clinical studies to clarify the role of resection in patients with 
malignant gliomas, but careful thought needs to be placed regarding study designs. 
Possible trial designs include true randomized trials of surgery (such as biopsy versus 
maximal safe resection in patients ineligible for gross total resection), randomized trials 
of surgical techniques designed to improve resection grades (117), or prospective 
community-based registration of all patients who undergo surgery (142). The latter 
provides high external validity, but difficulties establishing certain causality.  
 
 
Reporting of functional outcomes 
 
Functional and neurologic outcomes related to GBM surgery have been presented in 
numerous studies. However, it is difficult to compare functional outcomes as there is a 
considerable variation in inclusion criteria, classification of outcomes, and time of 
follow-up between different studies. Many published surgical series exclude biopsies or 
include only patients in whom gross tumour resection was attempted, complicating 
comparisons of results between studies and lowering external validity of the findings. 
Data from the Glioma Outcomes Project report of a potential selection bias as image 
guided resections tend to be carried out in patients with a more favourable prognosis 
(72). The better functional outcomes reported in papers 1 and 2 compared to paper 3, 
can probably be explained by a stricter patient selection. Even though specific scales 
exist for a number of neurologic conditions, there is no uniform method to define 
significant neurologic change for malignant glioma trials. Malignant glioma trials have 
yet to identify the functional outcome scale of choice for consistent use across studies.   
 
In papers 1 and 2 patients’ functional status was determined using the 7-step mRS. The 
mRS is primarily intended for measuring the degree of disability or dependence in the 
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daily activities of patients who have suffered a stroke, and it has become the most 
widely used clinical outcome measure for stroke clinical trials. It has been shown that 
the mRS has good interobserver agreement for the assessment of handicap in stroke 
patients (128). Patients’ functional status was not provided in paper 5 as this 
information is unfortunately unavailable in the Norwegian Cancer Registry. In papers 3 
and 4 patients’ functional status was described using the Karnofsky Performance Status 
(KPS). This is a widely evaluated metric across many oncology trials, and is an 
established prognostic factor for overall survival in high-grade gliomas. The KPS score 
was registered in a prospective fashion in paper 4. As the clinical presentation is highly 
dependent on the location of the tumour, the KPS and mRS scores might not adequately 
reflect the extent of disease or disease burden in all patients. As an example, a patient 
with a very small tumour in the motor cortex may have much lower scores on these 
metrics of functional status than a patient with a large tumour in one of the frontal lobes. 
 
One concern regarding our use of the mRS and KPS is that they were utilized in a 
retrospective manner in papers 1, 2 and 3. It is also difficult to distinguish reductions in 
mRS and KPS scores due to adverse effects of surgery from tumour progression, 
comorbid events, and concurrent adjuvant therapy. In papers 1, 2 and 3 we therefore 
also included information about specific neurologic deficits before and after surgery.  
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Evaluating adverse events 
 
We attempted to report adverse events in concurrence with Good Clinical Practice 
Guidelines in paper 3 (http://www.ema.europa.eu:  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	 Reporting), a system most often used in 
clinical drug trials. Adverse events are defined as any unexpected medical occurrence in 
a patient undergoing surgical treatment, which does not necessarily have a causal 
relationship with this treatment. An adverse event can therefore be any unfavourable 
and unintended sign, symptom, or disease temporarily associated with surgical 
treatment. Serious adverse events are defined as any unexpected medical occurrence in 
the operative period, which resulted in death, was life-threatening, required inpatient 
hospitalization or prolongation of existing hospitalization, or resulted in persistent or 
significant disability/incapacity. The subjectiveness of reporting is reduced since all 
events are reported, even though there may not always be a causal relationship between 
the treatment and the event.  The potential advantage of this classification is the ability 
to compare surgical results among different centres and time periods, as well as 
providing an opportunity to perform future meta-analyses. The Good Clinical Practice 
Guidelines provided a simple, practical, and reproducible way to report adverse events, 
comparable to interventional drug trials. Information from such a classification system 
of adverse events could provide valuable insight for neurosurgeons regarding how to 
manage and avoid surgical complications. It could also provide patients with more 
complete information about the risks of surgical complications.   
 
There are a few publications that attempt to classify complications associated with 
general neurosurgical and spinal interventions (15, 45). A recent study by Ibanez et al, 
which has received enthusiastic appraisal, introduces a new classification system for 
complications in neurosurgery (46). Their classification is based on a system from 
general surgery but modified to fit neurosurgical procedures (30). The authors suggest 
using a four-grade scale based on the therapy used to treat the complication. Adverse 
events are further divided into surgical or medical complications. This proposed 
classification system of complications has many of the same advantages and challenges 
as the Good Clinical Practice guidelines. Whereas the Good Clinical Practice guidelines 
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are applicable to almost any medical specialty, the classification system suggested by 
Ibanez has been tailored to better fit neurosurgical procedures. However, none of the 
two classification systems take preoperative morbidity into account and both rely on 
surgeon self-reporting.  
 
The main strength of paper 3 is the unselected, practically population-based inclusion, 
ensuring high external validity of results. However, due to the retrospective study 
design it is fair to assume that some adverse effects of surgery may have gone 
unnoticed. In paper 3 a comparison with other relevant studies with regards to adverse 
events is provided. For now, a systematic or unsystematic review of the incidence of 
adverse events in malignant glioma surgery remains difficult because such events are 
not always well defined, and assessments are often subjective, arbitrary, and probably 
under-reported. The numbers of adverse events vary considerably between studies, and 
this can probably be explained by differences in reporting and patient selection.  
 
 
Survival as an outcome parameter 
 
Overall survival 
In papers 2, 4, and 5 we presented data on overall survival for patients with high-grade 
glioma, whereas one-year and two-year survival were presented in paper 3 as follow-up 
time was limited for the patients operated in the last part of the study period. As overall 
survival reflects a clinically meaningful benefit that can be objectively and 
unambiguously assessed, it is generally considered the definitive primary end point for 
patients with malignant glioma. However, the use of overall survival as a primary end 
point has its drawbacks. A major challenge using overall survival as an end point is that 
many patients undergo multiple therapies, making it difficult to determine the 
attributable effect of a single treatment modality. In studies based on overall survival a 
longer follow-up time might be desired as compared to the other outcome parameters. 
As exemplified in the famous 5-ALA study (115), the impact of the intervention on 
overall survival may be less pronounced than its impact on resection grades and 
progression-free survival, resulting in the need for larger sample sizes. These factors 
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may increase required study duration, sample size, and cost. Factors such as age and 
preoperative performance status also affect survival time and may introduce greater 
variability in outcome. It is also important to keep in mind that start times may vary 
across studies and this can impact the presented overall survival.  
 
Progression-free survival 
Progression-free survival (PFS) measures time from treatment initiation to progression. 
There is evidence that PFS correlates with overall survival (5, 66). One of the main 
advantages using PFS as an end point is that studies can be completed in a shorter time 
frame. In addition, PFS-based studies require smaller sample sizes because a treatment 
effect is often greater on PFS than overall survival. Finally, PFS end points may be less 
affected by subsequent therapies or 2nd line treatments (e.g. re-do surgeries, 2nd line 
chemotherapy, repeated radiotherapy) compared to overall survival. The main reason 
for not using PFS as an end point in our studies is evaluation time bias due to non-
uniform patient assessment and follow-up. Studies on growth dynamics or progression 
free survival require standardized MRI protocols at predefined intervals. Another 
disadvantage of PFS end points are the non-uniform definitions of tumour progression 
used. Determination of PFS is dependent on a standardized method to define tumour 
progression. Current radiographic methods to define progression are problematic due to 
confounding factors such as pseudoprogression and pseudoresponse (96). Recently the 
Response Assessment in Neuro-Oncology (RANO) Working Group established new 
criteria to determine tumour progression in a more reliable and objective manner (135).  
 
Perioperative mortality 
Perioperative mortality or surgical mortality is usually defined as death occurring during 
the 30 first days after an operation. However, definitions such as death within 2 or 4 
weeks are also used. In publications based on administrative databases, in-house-
mortality is often used as this measure is more readily available. Surgery related 
mortality has historically been a highly relevant outcome measure in neurosurgery, 
allowing a comparison of outcome between surgeons and different surgical techniques. 
By 1910 Harvey Cushing had performed 250 brain tumour operations with a surgical 
mortality of 13%. In comparison, operative mortalities of contemporary surgeons were 
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approximately 50% (73). Still today, surgical mortality is a frequently studied and 
published outcome parameter. Surgical mortality has been endorsed as an Inpatient 
Quality Indicator by the US Agency for Healthcare Research and Quality for eight 
surgical procedures in adults, including craniotomies. Surgical mortality rates are also 
increasingly publicly reported as an indicator of hospital quality, despite often 
considerable limitations in data concerning differences in referral and case mix (37). 
 
While the pioneers in brain tumour surgery dealt with perioperative deaths quite 
frequently, early postoperative deaths now occur very seldom. The overall risk of 
perioperative death after first time surgery for primary intracranial tumours is currently 
around 2.2% (110). This low incidence greatly limits the power in comparative 
analyses, such as between patient series or between centers, and certainly between 
surgeons. Although, by consensus considered surgically related if occurring within the 
30 first days of surgery, most early postoperative deaths after brain tumour surgery may 
occur independent of the handwork of the operating surgeon. The overall prognosis of 
the tumour disease seems to be a strong predictor (110), perhaps to no surprise since the 
30-day mortality rate is merely the intonation of the Kaplan Meier curve. Both referral 
and treatment policies at a neurosurgical centre will therefore affect such early 
outcomes markedly. Further, the correlation between a hospital’s perioperative 
mortality rates and long term survival rates seems weak (110). The value of 
perioperative mortality rates as a quality indicator in modern neurosurgical tumour 
operations may therefore be questionable. 
 
 
Health related quality of life 
 
Whereas functional outcomes (e.g., KPS and mRS) and resection grades are measured 
by health care workers, health related quality of life (HRQL) is a patient reported 
outcome (PRO). Differences probably exist between the doctor and cancer patients’ 
assessment of their health. With a range of therapeutic options for patients with 
malignant glioma and with various risks of adverse effects, PROs can be used to 
evaluate different treatments (76). For patients with brain tumours, there are several 
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HRQL questionnaires available that can be used to assess the physical, psychological, 
and social impact of the disease and its treatment (96). HRQL is established as an 
outcome parameter for treatment comparisons in many malignant diseases, particularly 
in palliative settings (19). The most common cancer-specific HRQL tool is the 
European Organization for Research and Treatment of Cancer (EORTC) quality of life 
questionnaire (QLQ-C30) which also has an extensively validated supplement for 
patients with brain tumours (QLQ-BN-20) (122).   
 
In paper 4 we used the EuroQol 5D (EQ-5D) questionnaire to assess HRQL. This is a 
generic questionnaire (not developed for any specific patient group) that has been 
applied to a wide range of health conditions and treatments. The EQ-5D has also been 
validated in a Norwegian population (85). A recent study showed that EQ-5D correlated 
well with KPS in patients with glioma and was responsive to surgically induced 
neurological deficits (48).  
 
The usefulness of baseline HRQL data for patients with brain tumours remains a 
debated topic (76). There are conflicting data regarding the prognostic significance of 
baseline HRQL for patients with malignant gliomas and whether it may have additional 
value over other well known prognostic factors (21, 75). One study has shown that 
baseline HRQL was predictive of quality of life over time, and that gross total resection 
was associated with longer survival and improved quality over time for patients with 
high-grade gliomas (22). In previous studies baseline HRQL data were generally 
obtained after surgery. In paper 4, where baseline HRQL data were collected 
preoperatively, we found a negative effect on survival if HRQL deteriorated early after 
surgery in patients with GBM. Evaluation early after surgery most likely represents 
treatment related factors compared to later assessments that would be more likely to 
represent disease related factors. Thus, in 6 weeks we believe it is less likely that the 
majority of patients with deterioration in HRQL have experienced significant 
progression or adverse effects of adjuvant therapies. 
 
Susceptibility to response shift over time is one of the drawbacks of using HRQL to 
assess clinical benefit or deterioration in clinical trials. Another concern is selection bias 
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as patients in poor clinical condition are less likely to respond. Missing data are also a 
concern for the interpretation of patients’ HRQL, potentially introducing bias to the 
statistical analyses. Administrative failure is a common cause of missing data (132). 
The perception that the severity of the disease will affect the patient’s ability to fill out 
the questionnaire may also hinder the use of HRQL assessments. Patients who rapidly 
deteriorate are less likely to fill out the questionnaires than the fitter ones, and this may 
lead to an overestimation of patients’ HRQL (132).  
 
For many patients with high-grade gliomas, surgical resection is thought to relieve 
symptoms. Increased extent of tumour resection should be weighed against clinical 
performance and quality of life. It has even been suggested that in the palliative care 
setting, which is relevant for many patients with malignant glioma, clinical trials should 
be designed also with softer endpoints, such as HRQL, perhaps even with extended 
survival reported as a secondary end-point (55). The benefits of extended survival or 
progression delay have to be balanced alongside adverse effects of surgery. We 
therefore believe that HRQL assessments provide a meaningful end point in surgical 
trials of high-grade gliomas.  
 
  
Neurosurgical tools in high-grade glioma resection 
 
The main rationale for the use of intraoperative imaging is to correct for brain shift 
during tumour resection. In addition to intraoperative ultrasound, intraoperative 
visualization tools that can be applied when resecting of high-grade gliomas include 
fluorescence-guided surgery with 5-aminolevulinic acid (5-ALA) and intraoperative 
MRI. When performing surgery close to eloquent regions, intraoperative electrical 
motor cortex mapping and recording phase reversal of somatosensory evoked potentials 
are considered the gold standard. The classic procedure for language localization is 
intraoperative electrocortical mapping in awake patients, although seldom reported as 
routine procedure in suspected high-grade gliomas.  
 
 52
Papers 1, 2, and 3 are limited by their retrospective nature and the absence of control 
groups. Papers 1 and 2 are feasibility studies of technical applications presenting 
clinical data related to the use of this technology. We believe the external validity is 
fairly high in paper 3. Based on the research presented in this thesis, it is difficult to 
assess how surgery guided by 3D intraoperative ultrasound and preoperative BOLD 
fMRI and DTT compares to other surgical techniques with regards to resection grades, 
functional outcome, HRQL, and survival. To answer these questions a randomized trial 
or at least a pseudo-randomised population based registration with validated end points 
seem necessary. Using 3D intraoperative ultrasound also has some challenges and 
limitations. Whereas most neurosurgeons are used to interpreting CT and MR images, 
3D intraoperative ultrasound images may be unfamiliar to many and require some time 
to fully understand. Another disadvantage is that the acquired volume only covers the 
region of interest. This can be compensated by either displaying corresponding 
preoperative MR and ultrasound images, or superimposing the ultrasound volumes on 
the preoperative MR images. Further, there may be a decline in ultrasound image 
quality during the operation (101). The quality of ultrasound acquisitions in patients 
undergoing repeated glioma surgery with previously administered radiotherapy can be 
variable. The image quality also depends on a clean resection cavity without blood clots 
and cottonoids. Some thought also needs to be placed on patient positioning as the head 
should be positioned such that a vertical access to the lesion can be obtained. This 
allows air bubbles to rise to the surface when the operation cavity is filled with saline 
for ultrasound recordings.  
 
Recently, 5-aminolevulinic acid (5-ALA) has emerged as a drug with usefulness as a 
metabolic marker of malignant glioma cells that can be used intraoperatively to detect 
tumour tissue (118). This technique is based on the synthesis and accumulation of 
fluorescent and photosensitizing endogenous porphyrins after excess administration of 
5-ALA, a naturally occurring metabolite in the heme biosynthesis pathway. Patients 
receive orally administered 5-ALA three hours before surgery. Intraoperatively, 
fluorescence is observed through an operating microscope equipped with a fluorescent 
ultraviolet light and filters.  An RCT by Stummer et al showed how 5-ALA guided 
surgery enabled more complete resections of contrast-enhancing tumour, leading to 
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improved PFS in patients with malignant glioma (115). The study demonstrated early 
postoperative MRI to be devoid of contrast-enhancing tumour in 65% of patients with 
GBM in the 5-ALA group compared with 36% in a conventional microsurgical control 
group. Fluorescence-guided surgery can be combined with neuronavigation, 
intraoperative ultrasound, and awake surgery. There are some challenges associated 
with fluorescence-guided surgery (124). Timing of the oral administration of 5-ALA is 
important. Blood in the resection cavity reduces the fluorescence signal. There is also an 
exponential decline of excitation light intensity with growing distance; thus distance 
between the microscope and resection cavity should be kept small. Further, small 
corticotomies shade illumination light and also result in low fluorescence intensities. 
Ambient light within the operating room will interfere with the fluorescence signal, and 
care must be taken to reduce this. Due to the transient sensitization of the skin 
associated with the administration of 5-ALA, one should try to prevent excessive 
illumination of the patient’s skin. 
 
There are numerous publications on the added value of both low-field-strength (≤0.5 
Tesla) and high-field-strength (≥1.5 Tesla) intraoperative MRI-guided resection of brain 
tumours compared with conventional neuronavigation. Fibre tracking using diffusion 
tensor imaging has been reported on high-field strength MRI systems (83). In a 
thorough review by Kubben et al, several limitations and sources of bias which may 
lead to an overestimation of the attributable value of intraoperative MRI-guided surgery 
for resection of GBM are pointed out (62). One source of bias is attribution bias as 
intraoperative imaging may lead to a more conservative resection before the first 
intraoperative control scan is performed. This might lead to the conclusion that extent of 
resection is increased after intraoperative scanning. Attribution bias is also relevant for 
intraoperative 3D ultrasound recordings. Other concerns regarding research on 
intraoperative MRI-guided surgery are the various definitions of tumour volume and 
GTR. In addition, control groups may not be equivalent to study groups, mainly with 
regard to tumour location. Few studies provide explicit data on patients’ clinical 
performance and data on quality of life seems to be lacking. The review points out the 
need for randomized trials to show the added value of intraoperative MRI-guided 
surgery. In a recent study by Senft et al, 58 patients with suspected gliomas were 
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randomly assigned to undergo intraoperative low-field-strength (0.15 Tesla) MRI-
guided surgery or conventional microsurgery (without intraoperative ultrasound or 5-
ALA) (108). Higher resection grades and improved PFS were found in patients who 
underwent intraoperative MRI-guided surgery. There are some practical challenges with 
intraoperative MRI systems. For example, intraoperative MRI is an expensive 
technique. In addition, a longer preparation time before incision and longer preparation 
times before and immediately after image acquisition need to be taken into account (62, 
108).  
 
Several studies have reported the feasibility of intraoperative brain mapping and its 
possibly positive influence on clinical outcomes (33, 81, 91, 123). Patients with a high-
grade glioma close to an eloquent area such as the motor strip or sites possibly related to 
language function are potential candidates for brain mapping. Brain mapping is 
achieved by direct cortical stimulation with bipolar stimulation forceps, bipolar 
stimulation electrode or electrodes in form of stripes or grids. When applying 
stimulation, a function can be either elicited (such as motor response) or suppressed 
(such as execution of language). Positive cortical stimulation identifies cortical sites 
associated with and sites not associated with motor, somatosensory, or language 
function, whereas negative cortical stimulation typically identifies only sites not 
associated with such function. Thus, functionally relevant areas can be identified. The 
same can be achieved by stimulating white matter tracts. In a study published in 2008, 
Sanai et al advocate negative mapping through intraoperative cortical stimulation 
(negative cortical stimulation) instead of traditional positive cortical stimulation to 
preserve language function during glioma resection in or near language areas (104). 
Monitoring of language function requires the patient to be awake, oriented, and 
cooperative during the procedure of testing. This means that not all patients are eligible 
for brain mapping of language areas. Other challenges associated with awake surgery 
include epileptic convulsions due to cortical mapping and patient positioning on the 
OR-table. Patients who undergo brain mapping for identification of cortical motor 
function do not necessarily need to be awake during surgery. Motor evoked potentials 
can be recorded from muscles following direct stimulation of exposed motor cortex, and 
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somatosensory evoked potentials phase reversal can help identify the central sulcus. 
Interestingly, an RCT comparing resection under general versus local anesthesia awake 
surgery for tumours in eloquent areas showed that operative time and blood loss were 
less in the general anesthesia group. Better neurological outcome and a higher degree of 
resection were also achieved in the general anesthesia group (39). 
 
High-grade gliomas in the elderly 
 
The lack of sufficient evidence makes it difficult to establish recommendations for 
surgical treatment of GBM in the elderly. Each department has to determine if the 
quality of evidence is sufficient to influence their practice standards. There is still a 
need for clinical studies to clarify the role of resection in all patients with GBM, but 
careful thought needs to be placed regarding study designs. Possible trial designs 
include true randomized trials of surgery (such as biopsy versus maximal safe resection 
in patients ineligible for gross total resection), randomized trials of surgical techniques 
designed to improve resection grades (117), or more extensive prospective population 
based registrations (including performance status, quality of life registrations, 
volumetric tumour data, functional outcomes, and adverse events related to surgery) of 
all patients who undergo surgery. The evaluation of surgical resection must involve 
patients with demographic characteristics that are representative of the majority of 
patients with GBM, and elderly patients should not routinely be excluded. Providing 
guidelines on GBM resection to the elderly on the basis of trial information obtained 
mainly from younger patients does not necessarily constitute good clinical practice. One 
study tried to estimate how surgical resection affected postoperative survival compared 
to biopsy in patients over 65 years old with a suspected diagnosis of malignant glioma 
(131). In total, 30 patients were included in this study. The authors reported their 
findings as being in favour of resection. Due to methodological limitations, described in 
detail in a Cochrane review, the findings in this study are tainted by a high chance of 
being affected by bias (42). The findings of this trial are of insufficient reliability to be 
used to influence treatment decisions. However, the study should be viewed as evidence 
that randomised controlled trials in elderly patients with GBM are possible. 
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Recommendations for future research 
 
Based on the discussion in this thesis and the results presented in papers 1-5, a few 
recommendations for future studies on high-grade glioma resection can be made. First, 
if extent of tumour resection is to be used as an end point, a clear definition of 
postoperative tumour volume and a valid method to measure volume is of paramount 
importance. Second, more population-based prospective studies with high external 
validity and also randomized studies, such as the ones by Stummer (115) and Senft 
(108), are needed when comparing different types of surgical techniques. Third, 
outcome data should be more detailed and not only present functional outcome as 
judged by the surgeon, but also include PROs (i.e. HRQL). HRQL should be evaluated 
together with resection grades and survival to find a balance that can be used to 
benchmark treatment results in patients with high-grade gliomas. Fourth, adverse events 
should be recorded and presented in a uniform way. This will help evaluating different 
surgical techniques and provide valuable insight for neurosurgeons regarding how to 
manage and avoid complications. Studies should not solely focus on survival as there 
are several ways to improve patient care in patients with high grade glioma. In addition, 
standardized reporting of surgically based neuro-oncology trials should be encouraged 
(26).   
 
The Norwegian Cancer Registry is a valuable source of information, and has formed the 
basis of several neuro-oncology publications (50, 112). However, the quality of future 
research might be improved if more details regarding patient and tumour characteristics 
along with additional outcome parameters are sampled in the registry. Information 
about HRQL, pre- and postoperative functional levels, adverse events, tumour size and 
localization, surgical complexity (e.g., eloquence), operative technique, and resection 
grades could help further clarify the role of surgical resection of high-grade gliomas. 
Prognostic models have been constructed for patients with cerebral metastases (47), and 
the concept of constructing and investigating similar scales for high-grade gliomas 
based on population based registry data is intriguing. 
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Conclusions 
 
This thesis has investigated the role of surgical resection in the treatment of malignant 
astrocytomas and the following conclusions can be drawn: 
- The combination of blood oxygenation level-dependent functional magnetic 
resonance imaging, diffusion tensor tractography, and 3D ultrasound may 
facilitate resection of malignant astrocytomas harboured in eloquent areas while 
preserving motor and language function. 
- Functional neuronavigation combined with intraoperative 3D ultrasound can, in 
selected patients, enable resection of brain lesions with general anaesthesia 
without jeopardizing neurological function. 
- Patients with perioperative complications and surgically acquired deficits were 
less likely to receive adjuvant therapy. 
- Early deterioration in HRQL after surgery was independently and markedly 
associated with impaired survival in patients with glioblastoma. 
- Advancing age remains a very strong and independent negative prognostic 
factor in glioblastoma. Although there has been an increase in the 
aggressiveness of treatment provided to elderly with glioblastoma, the gain for 
the oldest age group seems at best very modest. The prognosis of the oldest age 
group remains very poor, despite multimodal treatment. 
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Abstract
Background: Studies indicate that acquired deficits negatively affect patients’ self-reported health related quality of life
(HRQOL) and survival, but the impact of HRQOL deterioration after surgery on survival has not been explored.
Objective: Assess if change in HRQOL after surgery is a predictor for survival in patients with glioblastoma.
Methods: Sixty-one patients with glioblastoma were included. The majority of patients (n = 56, 91.8%) were operated using
a neuronavigation system which utilizes 3D preoperative MRI and updated intraoperative 3D ultrasound volumes to guide
resection. HRQOL was assessed using EuroQol 5D (EQ-5D), a generic instrument. HRQOL data were collected 1–3 days
preoperatively and after 6 weeks. The mean change in EQ-5D index was 20.05 (95% CI 20.15–0.05) 6 weeks after surgery
(p = 0.285). There were 30 patients (49.2%) reporting deterioration 6 weeks after surgery. In a Cox multivariate survival
analysis we evaluated deterioration in HRQOL after surgery together with established risk factors (age, preoperative
condition, radiotherapy, temozolomide and extent of resection).
Results: There were significant independent associations between survival and use of temozolomide (HR 0.30, p = 0.019),
radiotherapy (HR 0.26, p = 0.030), and deterioration in HRQOL after surgery (HR 2.02, p = 0.045). Inclusion of surgically
acquired deficits in the model did not alter the conclusion.
Conclusion: Early deterioration in HRQOL after surgery is independently and markedly associated with impaired survival in
patients with glioblastoma. Deterioration in patient reported HRQOL after surgery is a meaningful outcome in surgical
neuro-oncology, as the measure reflects both the burden of symptoms and treatment hazards and is linked to overall
survival.
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Introduction
Surgical studies in patients with glioblastoma have focused
much on resection grades and maximal safe resection is usually
advocated. However, measurements of both extents of resection
and safety vary between studies and there are few controlled trials.
Due to non-uniform inclusion criteria and assessments of
outcomes, direct comparison of results and techniques are difficult,
if not impossible [1]. Nevertheless, it seems like resections need to
be extensive to improve survival, but the resection grade threshold
for a probable clinical benefit remains debated [2–4]. Safety is less
often assessed and there is no uniform and accepted method for
reporting of adverse events in surgical trials [5]. Often clinicians or
operating surgeons report clinical outcomes in gross functional
scales with a potential of assessment and interest bias.
The combination of this ultimately fatal disease with the delicate
balance between potential effect and hazards of surgery makes
patients’ perioperative HRQOL of particular interest. However,
the impact of glioblastoma surgery on patient reported outcomes
has not been explored much [6]. We have earlier described
possible predictors of HRQOL in patients undergoing glioma
surgery. The study clearly demonstrated the devastating effect of
acquired deficits on patient reported HRQOL [7]. A recent paper
found that surgical acquired deficits may be associated with
decreased survival as well [8], but the possible impact of
postoperative loss of HRQOL on survival has not been explored.
In the present prospective study we aimed to assess if changes in
HRQOL after surgery added any prognostic information to the
already established risk factors.
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Materials and Methods
Ethics statement
All patients included have given their written and informed
consent. The Data Inspectorate in Norway approved registration
and management of data. The study was approved by the
Regional Ethical Committee for Health Region Mid-Norway.
Methods
Study subjects were recruited from patients aged $18 years
admitted to our department for scheduled brain tumor surgery, in
the period from January 2007 through December 2010. Patients
were followed until death or until May 15th, 2011. Survival was
calculated from the date of surgery. Only patients with
histopathological confirmed glioblastoma according to the WHO
classification were included in this study. Patients provided written
informed consent and filled out the EuroQol 5D (EQ-5D)
questionnaire 1–3 days before surgery. A study nurse scored
preoperative Karnofsky Performance Status (KPS) on admission.
Patient follow-up by a study nurse was scheduled at 6 weeks
(median time to follow up: 47 days) after surgery. We decided to
use 6 weeks to allow for some recovery from transient surgically
induced deficits. In addition, few patients experience significant
tumor progression in this time frame. At this time point some
patients may have started adjuvant therapy and this could
influence the HRQOL, however this is expected to be the same
between the groups and therefore unlikely to influence the results.
Adverse effects are also quite rare during the initiating phase of
adjuvant radiotherapy and/or concomitant temozolomide treat-
ment. Structured interviews were used to assess HRQOL (EQ-5D)
using the same questionnaire as preoperatively. The patients were
also interviewed about possible complications, acquired and/or
worsened deficits (motor, language, vision, unsteadiness and other)
and altered mental functions (memory, personality and other)
experienced after the procedure. Only patients with complete
HRQOL data were included in the analyses. Tumor volumes and
resection grades were determined from preoperative and early
postoperative MRI volumes using an ellipsoid model (4 6r3/3), as
described by others [9]. Gross total resection (GTR) was defined as
no visible contrast enhancing tumor tissue on the early
(,72 hours) postoperative 1.5 T or 3.0 T MRI scans.
Study population
Sixty-seven patients with glioblastoma were included from
baseline, but 6 (9.0%) patients did not complete the EQ-5D
questionnaire after surgery. All patients who did not respond were
dead at last follow-up. Three were lost to follow-up as they were
already dead or in a terminal condition at 6 weeks, whereas the
other three patients who were lost to follow- up lived for a median
30 weeks. The only in-hospital registered complication among
these six patients was seizures in one patient who had no seizures
preoperatively. Median preoperative HRQOL for these six
patients was 0.59 (range 0.27–0.74).
Sixty-one patients had complete EQ-5D forms before and after
surgery and were included in the analyses. Clinical characteristics
are presented in Table 1. The mean age of included patients was
58 years (range 26–81) and 29 (47.5%) were female. The median
preoperative KPS was 80 and 84.7% were functionally indepen-
dent (KPS 70–100). Thirty eight (62.3%) of the operations were
primary and 23 (37.7%) were reoperations.
Surgical procedure
All operations were performed under general anesthesia. The
SonoWandH neuronavigation system was available if requested by
the surgeon and was used in 56 (91.8%) of the operations. The
system utilizes 3D preoperative MRI and updated intraoperative
3D ultrasound volumes to guide resection [10]. In eloquent lesions
functional neuronavigation was incorporated utilizing a method
described in detail earlier [11,12]. Functional MRI and diffusion
tensor imaging data was incorporated into the system in 19
(31.1%) and 23 (37.7%) of the operations respectively. Sixty
(98.4%) of the 61 included patients underwent craniotomy and
tumor resection. One patient underwent biopsy only. The median
preoperative tumor volume was 18.4 cm3 and the median
resection grade was 96.3% with GTR achieved in 24 (39.3%) of
the patients.
The EuroQol 5D
EQ-5D is a generic (not developed for any specific patient
group) and preference-weighted measure of HRQOL [13]. The
questionnaire has been applied to a wide range of health
conditions and treatments as well as population based health
surveys [14,15]. There are many different instruments available
for researchers interested in assessing HRQOL. We chose to use
EQ-5D due to the simplicity of the instrument, to enhance patient
perception and perhaps also compliance. Generic instruments
such as EQ-5D lack disease specific questions that may be relevant
to the patient group (e.g. cognitive functions). Generic instruments
may therefore lack sensitivity to measure small benefits or negative
consequences of surgery. However, we have earlier demonstrated
that EQ-5D shows good correlation to KPS in patients with
gliomas and is responsive to new neurological deficit which is
highly relevant in this patient group. Also, compared to KPS it
offers a more nuanced picture with respect to change after surgery.
Since KPS only measures one physical dimension of HRQOL it is
insensitive to changes in other dimensions [7]. Another important
difference between EQ-5D and KPS is that the latter most often is
reported by the physician whereas the former is a patient reported
outcome. The EQ-5D has been validated in a Norwegian normal
population [16], but so far not in glioma patients. In EQ-5D, five
dimensions of HRQOL are scored; mobility, self-care, usual
activities, pain/discomfort and anxiety/depression with 3 possible
answers to each dimension, i.e ‘no problem’, slight problem’ or
‘major problem’. This results in the 243 different possible health
Table 1. Clinical characteristics of the patient population.
Clinical characteristics No. (%)
Age (mean, range) 58 years (28–81)
Female 29 (47.5)
Preoperative KPSa (median, range) 80 (50–100)
Assumed eloquentb 33 (54.1)
Primary operation 38 (62.3)
Tumor volume (median, range) 18.4 cm3 (1.1–233.5)
Gross total resection 24 (39.3)
Radiotherapy (now or prior) 56 (91.8)
Temozolomide (now or prior) 46 (75.4)
Acquired neurological deficits 23 (37.7)
Complications 15 (24.6)
Complications leading to reoperation 2 (3.3)
aKPS, Karnofsky Performance Status.
bEloquence is here defined as grade II and grade III according to the definition
by Sawaya et al. [37].
doi:10.1371/journal.pone.0028592.t001
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states which are transformed into a single index value based on a
large survey in the UK population [17]. EQ-5D index value is
from 20.594 to 1, where 1 corresponds to perfect health, and 0 to
death. Negative values are considered to be worse than death. To
provide examples a patient scoring 2, 1, 1, 1, and 2 receives a score
of 0.78, while a patient scoring 2, 3, 3, 2 and 2 receives a score of
0.08. A visual analogue scale where patients rate their current
health state on a line ranging from 0–100 (worst to best imaginable
health) forms the second part of the EuroQol questionnaire. In this
study only the index value was assessed.
Statistics
All analyses were done with the PASW statistics, version 18.0.
Statistical significance level was set to P,0.05. Q-Q plots were
used to test for normal distribution of data. Central tendencies are
presented as means if data is normally distributed and as medians
when skewed. When analyzing changes in EQ-5D (e.g. before and
after surgery) paired sample t-test was used. For comparison of
groups with skewed distribution we utilized Mann-Whitney U test.
For binominal data we used Pearson’s chi square test.
In the Cox multivariate survival analysis the variables were
chosen on the basis of current evidence. The most consistent factors
affecting survival in patients with glioblastoma are age [18] and
preoperative functional status, usually evaluated with Karnofsky
Performance Status (KPS) [19,20]. High quality evidence for the
efficacy for adjuvant treatment with radiotherapy and temozolo-
mide in selected patients is now available [21,22]. There is also
growing evidence suggesting that achieving gross total resection
improves survival [2,23]. We performed univariate analyses for
each risk factor and included all in the multivariate model. The Cox
multivariate model included the following variables: Age (linear),
extent of resection (linear), radiation (yes, no), temozolomide (yes,
no), preoperative Karnofsky (linear) and deterioration in patient
reported HRQOL (yes/no). We are aware that use of linear data is
preferable for statistical reasons (no loss of information), but
dichotomizing variables makes clinical interpretation easier,
especially when scores consist of several summarized variables,
making the immediate interpretation of a number less intuitive. For
radiation and temozolomide ‘‘yes’’ indicates that the treatment has
been provided at any time during the course of the disease.
Results
HRQOL evaluated with EQ-5D
The mean preoperative EQ-5D index was 0.67 compared to
0.62 postoperatively. The mean decline of20.05 (95% CI20.15–
0.05) is a non-significant change (p= 0.285). There was a wide
range in the difference (20.96 to 0.87) after surgery. There were
30 patients (49.2%) who reported a deterioration 6 weeks after
surgery while 9 (14.8%) were unchanged and 22 (36.1%) reported
improved HRQOL. Treatment and outcome characteristics
comparing the patients with deterioration in HRQOL with the
others are presented in Table 2. Patients who reported
deterioration in HRQOL had EQ-5D index 0.41 postoperatively
as compared to 0.81 in their counterparts (p,0.001). The group of
patients who experienced a deterioration in HRQOL after surgery
(n = 30) more often had acquired deficits (p = 0.017). There was
also a trend for better HRQOL preoperatively (p = 0.051),
although not statistically significant.
Survival
At the end of follow up 22 patients (36%) were still alive.
Median survival was 64 weeks (95% CI 44–84) and a survival
curve is presented in Figure 1.
In a Cox multivariate survival analysis we evaluated the impact
of the established risk factors together with deterioration in
HRQOL. The results are presented in Table 3 and Figure 2A, 2B
and 2C. There were independent associations between survival
and use of temozolomide (HR 0.30, p= 0.019, Figure 2A),
radiation therapy (HR 0.26, p = 0.030, Figure 2B), and deterio-
ration in HRQOL after surgery (HR 2.02, p = 0.045, Figure 2C).
Patients with deterioration in HRQOL more often died during the
first six months following surgery (TYable 2, p = 0.017). Preoper-
ative KPS or surgical extent of resection did not reach statistical
significance. Using KPS as a dichotomous variable (KPS$70) or
categorical values for extent of resection (gross total, subtotal and
biopsy) did not change the conclusion. Inclusion of surgically
acquired deficits in the model did not alter the conclusion either,
and actually strengthened the association between deterioration in
HRQOL after surgery with overall survival (HR 2.4, p = 0.022).
Since requested in the review process, primary and redo
operations were analyzed separately. Ad-hoc testing verified that
temozolomide and radiation therapy were statistically significant
predictors (p,0.05) when the 38 primary operations were
analyzed separately. Deterioration in HRQOL did not reach
statistical significance (HR 2.9, p= 0.05). No statistically significant
predictor was found when analyzing the 23 reoperations
separately.
Discussion
In this prospective follow-up study of 61 glioblastoma patients
we found that deterioration in HRQOL early after surgery seems
to be an independent negative prognostic factor for survival.
Deterioration in HRQOL occurs in about half of the patients
despite the use of modern image guided surgery. The effect of
deteriorating HRQOL was independent of the established risk
factors, such as age, extent of resection, preoperative functional
status (KPS), and adjuvant treatment. The difference in survival
appears to be due to a difference in early mortality. A decline in
HRQOL in the early postoperative phase may be suggestive a
rapidly growing lesion or perhaps negative effects from surgery. It
has been reported that acquired deficits can be associated with
both suboptimal adjuvant therapy [5] and reduced survival [8].
Still, we found that the negative impact of lost HRQOL remained
significant after adjustment for reported acquired neurologic
deficits. Our findings indicate that evaluation of the patients’
perception of own health may be of high prognostic value. If so,
this may allow for new and interesting outcome measures in
glioblastoma surgery that reflect the biology of the disease, the tolls
and the benefits from surgery, while maintaining the relevance for
overall survival. HRQOL measures allow for comparisons across
studies and techniques while avoiding the potential bias associated
with surgeons’ evaluation of own results.
Overall survival is considered the gold standard when
evaluating treatment of glioblastoma and its role is indisputable.
However as survival benefits from surgery can be modest, survival
as study end-point may require multicentre inclusion and years of
recruitment to avoid a statistical power shortage, as experienced in
the 5-ALA study [9]. Further, this measure can be quite unspecific
in a surgical setting as it reflects the results from non-surgical
interventions as well. Progression free survival (PFS) may be used
instead as in the 5-ALA-study [9], but the definitions vary and
interpretation is problematic [24]. Pseudoprogression occurs in
approximately 20% and this makes a pure imaging based outcome
unreliable [25]. There may be contrast enhancement due to the
treatment itself which can be impossible to distinguish from
recurrent disease [24]. Another problem is pseudoresponses, seen
Survival after Postoperative Loss of Health
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with antiangiogenic agents where the disappearance of contrast
enhancement is not necessarily related a clinical response [24,26].
However, the dynamics of tumor progression, the speed of growth,
and patterns of growth may be of prognostic importance if a
reliable measure becomes available.
Extensive resections are advocated by numerous studies due to
the association with improved survival. The association seems
logical, but it is difficult to differentiate the efficacy of treatments
from treatment selection as most studies are neither randomized,
controlled nor prospective [4,23,27]. As mentioned earlier,
differences in patient selection are obstacles for meaningful
comparisons between institutions and techniques. Lastly, with
the exception of the 5-ALA study [9] most studies are not even
designed to evaluate the efficacy of surgical treatment. The present
study does not indicate that extensive resection negatively affects
HRQOL in itself, but it indicates that there is serious potential for
harm in surgical treatment of glioblastomas. We believe careful
therapeutic considerations should be made in cases where safe
gross total resection seems unlikely as the risk might outweigh the
benefit.
These common end-points all have drawbacks which can be
problematic for meaningful clinical interpretation. Since the
prognosis with respect to survival remains unfavorable despite
maximal therapeutic efforts, measuring patients’ quality of survival
is an important supplement [6]. We believe HRQOL adds useful
information both for clinical use and research. Met with the
individual patients, neurosurgeons should take into account the
potential hazards of surgery on patients’ HRQOL and carefully
weigh this up against the likelihood of a survival benefit. Perhaps
the patients’ subjective HRQOL reflects the dynamics of their
disease of prognostic importance, although difficult to quantify
even in serial MRI scans. HRQOL reflects both the burden of
treatment and the severity of the disease and together with the
association to overall we believe that deterioration in HRQOL, or
deterioration free survival after surgery, can be a meaningful
endpoint in surgical trials in neuro-oncology.
In demonstrating prognostic potential of self reported HRQOL
we are in line with earlier studies [28–31]. However, we are not
aware of any other study assessing the prognostic effect of
HRQOL where baseline scores are collected preoperatively.
Other neuro-oncological studies evaluating HRQOL and survival
are usually in the setting of medical clinical trials using initiation of
chemotherapy or radiotherapy as baseline [29–32]. This neglects
Table 2. Comparisons of treatment related factors and outcome among patients experiencing deterioration in HRQOL after
surgery with patients with equal or better HRQOL after surgery.a
Deterioration in HRQOL
(n=30) Equal or improved HRQOL (n=31) P-value
Primary operationb 17 (56.6%) 21 (67.7%) 0.375
KPS (median) preopc 80 90 0.586
Tumor volume (median)c 24.1 cm3 15.9 cm3 0.322
Extent of resection (median)c 95.1% 96.5% 0.715
Gross total resectionb 11 (36.7%) 13 (41.2%) 0.532
Complicationb 8 (26.7%) 7 (22.6%) 0.401
New/worse deficitb 16 (53.3%) 7 (22.6%) 0.017
EQ-5D index (mean) preopd 0.75 0.59 0.051
EQ-5D index (mean) postopd 0.41 0.81 ,0.001
Deaths in month 0–6b 11 (36.7%) 3 (9.7%) 0.012
Deaths in month 7–12b 6 (20.0%) 5 (16.1%) 0.694
Deaths .12 monthsb 6 (20.0%) 8 (25.8%) 0.590
Total deaths in follow upb 23 (76.7%) 16 (51.6%) 0.042
aHRQOL, health related quality of life; KPS, Karnofsky Performance Status; p,0.05 is considered significant.
bPearson chi-square.
cMann-Whitney U test.
dIndependent sample t-test.
doi:10.1371/journal.pone.0028592.t002
Figure 1. Overall survival in the cohort (n =61) presented in a
survival plot.
doi:10.1371/journal.pone.0028592.g001
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the potential effect and hazards of surgery which undoubtedly is
the most invasive form of treatment in patients with glioblastoma.
Patients may perceive their health and HRQOL differently with
regards to sex, tumor location and histopathology [6,7]. Therefore
it is difficult to find an optimal cut-off-value with clinical
significance, and searching for a so called ‘‘best cut-off’’ may be
somewhat dubious and increase the risk for false positive findings
[33]. Utilizing changes instead of absolute values seems clinically
more useful in individual patients. This approach takes individual
differences into consideration as patients are their own controls.
This approach may reduce the problems mentioned above.
However, interpreting changes in HRQOL is not necessarily
straightforward. Changes should be evaluated as clinically
meaningful rather than simply statistically significant. This can
be achieved by anchoring HRQOL to therapy, changes with
disease progression or life events [34].
EQ-5D, a generic HRQOL measure, shows good correlation
with traditional outcome measures [7], and in this study it also
demonstrates an association with hard clinical end-points. Thus it
is seemingly a valuable tool in assessing HRQOL in patients with
glioblastoma. Despite potential shortcomings of generic instru-
ments, we are convinced that patient related outcomes with a
validated questionnaire are interesting, valuable, and perhaps less
biased adjuncts to traditional physician rated outcome measures.
The use of EQ-5D for the entire glioblastoma patient population
should be subject of further studies i.e. defining minimal important
change or measuring HRQOL at multiple time points to better
understand the HRQOL throughout the course of the disease.
However, we would insist on using a preoperative evaluation as
baseline to avoid loss of important information.
The relative high number of complications and acquired deficits
in our patients are most likely explained by the assessment method
used. All adverse events were patient reported, including
uncommon outcome parameters used in the neurosurgical
literature, namely memory difficulties, unsteadiness and personal-
ity changes. When using a more common method of assessment
we have reported complications in 21% and deteriorated
functional outcome in 13% in a consecutive, unselected series in
patients with high grade gliomas [1]. Comparing adverse events
between studies is difficult due to different inclusion criteria and
the lack of a standardized way of reporting [5]. With this in mind
we believe these findings are comparable to a large study where
34% of patients experienced perioperative complications and
9.9% displayed worsened neurological status within 3 weeks after
primary craniotomy for malignant glioma [35]. For the future we
would encourage researches to use one standard way of reporting
since this would facilitate meaningful comparisons, i.e. using the
system for neurosurgical patients recently described [36].
Our study has several limitations. The patients included
represent an unsystematic selection that may not be representative
for the entire population of patients with glioblastoma. We believe
the lost-to follow-up rate of 9% is low. How these lost-to-follow-
Figure 2. Survival curves for the independent predictors presented in Table 3.
doi:10.1371/journal.pone.0028592.g002
Table 3. Cox multivariate regression.a
HR univariate P-value
HR
Multivariate P-value 95% CI for multivariate HR
Lower Upper
Age 1.04 0.023 1.00 0.990 0.97 1.03
EOR 0.99 0.176 0.99 0.403 0.97 1.00
Radiotherapy 0.12 ,0.001 0.26 0.030 0.08 0.88
Temozolomide 0.20 ,0.001 0.30 0.019 0.11 0.82
KPS preoperative 0.98 0.083 0.99 0.325 0.96 1.01
HRQOL deterioration 2.11 0.022 2.02 0.045 1.02 4.00
All variables included in the model are presented both for univariate and multivariate analyses. Radiotherapy, use of temozolomide and deterioration in quality of life 6
weeks after surgery were independently associated with overall survival.
aEOR, extent of resection; KPS, Karnofsky Performance Status; HRQOL, health related quality of life; HR, hazard ratio; CI, confidence interval; p,0.05 is considered
significant.
doi:10.1371/journal.pone.0028592.t003
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ups would have affected the results remains speculative, but as
three were dead or in a terminal condition, it is reasonable to
believe their HRQOL had deteriorated as well and further
strengthened the association. Adjuvant treatment (yes/no) was
included in the Cox regression model in spite of the risk of
survivorship effect overestimating the actual effect of the
intervention. A case-mix with 37.7% reoperated patients where
most had already received adjuvant treatment could possibly lead
to underestimation of the effect of adjuvant treatment. Although
the effect of lost HRQOL seems independent of given adjuvant
treatment, details of treatment protocols were not studied. We
therefore advise to interpret the effects of adjuvant therapy in this
study with some caution. Results from the ad-hoc analyses for
primary operations and reoperations separately, as requested in
the review process, may likely be due to type II errors and should
not alter the interpretation of the study. They suggest that the
findings in this study may be more representative for primary
operations than for reoperations, but this finding needs to be
verified in a larger study. Finally, the statistical method used in
creating a dichotomous variable (worse HRQOL: yes/no) from a
single variable is associated with an increase in false positive
findings [33]. However the cut-off chosen is not created on the
basis of finding the ‘‘optimal’’ cut-off, but out of logic and what we
thought would be of clinical relevance. Another important
statistical culprit is the floor-ceiling effect since patients in a good
preoperative condition can only become worse and vice versa.
Conclusion
Balancing risks with potential survival benefit and clinical
improvement is the key in surgical treatment of patients with
glioblastoma. Resection grades, overall survival, and PFS are
much used outcome parameters in surgical research, but they offer
no information on quality of survival. In this study we have
demonstrated that early deterioration in HRQOL after surgery is
independently and markedly associated with impaired survival.
Deterioration in patient reported HRQOL after surgery is a
meaningful outcome in surgical neuro-oncology as HRQOL
reflects the burden of symptoms, the treatment hazards and is
linked to survival.
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